Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fixed eruptions: causative drugs and challenge tests.

K Kauppinen, S Stubb

    The British Journal of Dermatology
    |May 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Requirement for Akt-mediated survival in cell transformation by the dbl oncogene.

    Cellular signalling·2006
    Same author

    [Cutaneous and cerebral cryptococcosis during corticosteroid therapy].

    Duodecim; laaketieteellinen aikakauskirja·2002
    Same author

    Long-term results in patients with onychomycosis treated with terbinafine or itraconazole.

    The British journal of dermatology·2002
    Same author

    [Tinea capitis in immigrants].

    Duodecim; laaketieteellinen aikakauskirja·2001
    Same author

    Fixed drug eruption due to phenylpropanolamine hydrochloride.

    The British journal of dermatology·2000
    Same author

    Fixed drug eruption due to fluconazole.

    Journal of the American Academy of Dermatology·2000

    Phenazones and barbiturates are the primary culprits behind fixed drug eruptions, including severe bullous forms. These findings, confirmed by challenge, align with previous research, highlighting key drug triggers.

    Area of Science:

    • Dermatology
    • Pharmacology
    • Clinical Medicine

    Background:

    • Fixed drug eruption (FDE) is a specific type of adverse drug reaction.
    • Generalized bullous FDE can mimic severe conditions like Lyell's syndrome.
    • Identifying causative agents is crucial for patient management and prevention.

    Purpose of the Study:

    • To identify the drugs responsible for fixed drug eruptions in a series of patients.
    • To confirm causative agents through drug challenge.
    • To analyze the most frequent and severe drug triggers.

    Main Methods:

    • Retrospective analysis of 86 cases of fixed drug eruption.
    • Drug challenge tests to confirm causality in most cases.
    • Classification of cases, including generalized bullous FDE.

    Related Experiment Videos

    Main Results:

    • Eighty-six cases of FDE were analyzed, with causality confirmed in all but two.
    • Phenazones and barbiturates were identified as the main causative drugs.
    • These drugs were implicated in both the overall series and the most severe bullous cases.

    Conclusions:

    • Phenazones and barbiturates are significant causes of fixed drug eruption.
    • The findings are consistent with previous epidemiological data on FDE triggers.
    • Awareness of these common drug culprits is essential for clinical practice.